Prostate Cancer Clinical Trials & Research

Prostate patients are carefully monitored by physicians and prostate cancer researchers throughout the clinical trial.

Prostate cancer clinical trials are used to determine just how effective promising new therapies can be. Although they are often thought of as experimental studies, clinical trials are actually conducted after a treatment has been deemed safe. Patients are carefully monitored by physicians and prostate cancer researchers throughout the entire process. Patients are never obligated to participate, and can end their participation at any time.

Is a Clinical Trial the Right Option for Your Prostate Cancer Treatment?

Clinical trials are not only safe and carefully regulated, but also an important step in determining how a new treatment can best be used to help patients. During a clinical trial, investigators will learn:

  • Which doses of the treatment are most effective
  • Which patients respond best to the treatment (e.g., patients with a certain stage of cancer, or patients whose tumors are made up of a certain kind of cells)
  • Whether the treatment provides the best results on its own or when combined with other therapies
  • What side effects might occur, and how they can be managed

As a National Cancer Institute-designed Comprehensive Cancer Center, Moffitt Cancer Center is constantly conducting clinical trials to study the newest treatments for prostate cancer. For instance, we have investigated the role of hormone therapy in patients with rising prostate-specific antigen (PSA) levels after their first attempt at treatment, as well as the effectiveness of bone-strengthening therapies to help reduce the likelihood that prostate cancer will spread to the bones. These are just a small sampling of the trials we’ve conducted; we continually strive to offer our patients more effective treatment options, and our robust clinical trials program is one of the main ways we are able to do so.

To learn more about our prostate cancer clinical trials, call  1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. No referral is required; our clinical trial navigators will be happy to help you find a trial that may suit your treatment goals.

 

calledFromCancerPage=True - substr=prostate
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19435

Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 20056

Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 20117

A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 20832

A Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 21139

A Phase IIA Study of Sequential ("first strike, second strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21559

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 21636

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Disease Site: Breast, Colon, Prostate, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21899

Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation

Disease Site: Breast, Other Female Genital, Ovary, Pancreas, Prostate

View Trial Details

CLINICAL TRIAL 21989

Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 19291

The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men with High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 20010

IRONMAN: International Registry for Men with Advanced Prostate Cancer

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 21876

Exploring Men s Prostate Cancer Genetic Risk Perceptions and Willingness to Give a Biospecimen for Genetic Risk Testing

Disease Site: Prostate

View Trial Details

CLINICAL TRIAL 50428

Metabolite Consumption in Patient-Derived Explants to Predict Therapeutic Response in Aggressive and Oligometastatic Prostate Cancer in African American Men

Disease Site: Prostate

View Trial Details